Mayo Clinic | Strategic Alliance Partners

Practical strategies to improve clozapine education, monitoring, and utilization while addressing common barriers and safety concerns.

Jonathan Leung, PharmD, RPh, BCPS, discusses the ongoing underutilization of clozapine despite its efficacy, highlighting clinician concerns, lingering perceptions, and the key role pharmacists play in improving its use through education and monitoring.

FDA-approved elinzanetant offers stronger nonhormonal relief for menopausal vasomotor symptoms, with promising trial results and simpler liver monitoring.

WHO’s 2025 pregnancy diabetes guidance explains glucose monitoring, hemoglobin A1C targets, and metformin/insulin choices, with a focus on low-resource care.

Technological change and COVID-19–related staffing challenges have intensified the need for pharmacy technician career growth and retention strategies. Mayo Clinic implemented an inclusive 5-tier career ladder with expanded training and compensation, reducing turnover by nearly 50% and improving satisfaction, demonstrating the impact of structured advancement on workforce stability and professional development.

Discover how the new PREVENT equations enhance cardiovascular risk assessments, improving patient screenings and prevention strategies for diverse populations.

To effectively and safely taper benzodiazepines, withdrawal challenges must be addressed while promoting patient involvement.

New oral GLP-1 agonist orforglipron cuts A1C and drives meaningful weight loss in trials, offering easier dosing than injections.

Pharmacists play a vital role in precision oncology, enhancing treatment decisions for metastatic breast cancer through genetic testing and targeted therapies.

Explore the impact of GLP-1 medication on weight loss in menopausal women, highlighting the need for personalized treatment approaches.

Megan Dulohery Scrodin, MD, highlights Mayo Clinic's innovative COPD care model, emphasizing multidisciplinary collaboration and AI tools for improved patient outcomes.

Megan Dulohery Scrodin, MD, discusses COPD management challenges and the need for accessible care and cost reduction.

Oncologist Thor Halfdanarson reviews dose-finding data for the targeted α radioligand therapy [^212Pb]VMT- α-NET, highlighting manageable toxicity, stable renal function, and plans for phase 2 evaluation.

Pharmacists enhance patient care by managing CDK4/6 inhibitors, addressing adverse effects and ensuring effective therapy selection in oncology.

Expert shares the evolving role of pharmacy in patient care, emphasizing treatment accessibility and monitoring.

Outpatient use of bispecifics and CAR T-cell therapies in multiple myeloma can expand access.

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses how Medicaid payment changes could impact rural hospitals and local pharmacies, noting the importance of pharmacists staying involved as the situation develops.

Scott Soefje, PharmD, MBA, BCOP, shares insights about the evolving role of pharmacists at the 2025 OPC meeting.

Heidi Finnes, PharmD, BCOP, FHOPA, discusses the evolving landscape of treatment of cutaneous malignancies.

Scott A. Soefje, PharmD, MBA, BCOP, explained how the expanding use of the FDA’s 505(b)(2) drug approval pathway is creating operational and reimbursement challenges for oncology infusion centers.

Nilufer Ertekin-Taner contrasts current one-size-fits-all Alzheimer disease treatments with the promise of precision medicine and emphasizes the vital role of collaborative, multidisciplinary care.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, offers insights for oncology pharmacists treating patients with metastatic esophageal squamous cell carcinoma.

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses a case study of a patient with metastatic esophageal squamous cell carcinoma.

Nilufer Ertekin-Taner outlines how embracing the biological complexity of neurodegenerative diseases can guide the development of precision therapies akin to those used in oncology.

Nadofaragene firadenovec led to most patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer (NMIBC) experiencing a complete response (CR) at 3 months.

The rising use of prescription stimulants in the US presents significant safety risks, legal challenges, and supply chain shortages, emphasizing the need for pharmacist involvement in promoting responsible prescribing.

Yi Lin, MD, PhD, highlights the importance of achieving MRD negativity in multiple myeloma, CAR T-cell therapy outcomes, and the critical role of pharmacists in patient care.

Eculizumab (Soliris; Alexion), a C5 inhibitor preventing cleavage into C5a and C5b, is widely considered the first-line therapy for high-risk TA-TMA.

As of now, data suggest minimal risk of drug interactions between oral contraceptives and injectable semaglutide.